

GLAXOSMITHKLINE PLC  
Form 6-K  
February 05, 2009

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending February 2009

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

**Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons**

I give below details of changes in interests in the Ordinary shares of GlaxoSmithKline plc in respect of the under

-  
mentioned  
persons, arising  
from the purchase of Ordinary shares on  
4 February 2009  
following the reinvestment of dividends,  
under a Single Company  
ISA  
at a price of £12.50  
per Ordinary share:

Mr A P Witty            6

Mr J S Heslop         6

Mr S                     32

M Bicknell

Mr E J Gray            6

Mr D S Redfern       6

The Company and  
the above named persons  
were advised of this information  
on  
5 February 2009.

This notification relates to a transaction notified in accordance with

Disclosure  
and Transparency

Rule 3.1.4R(1)(a).

V A Whyte  
Deputy  
Company Secretary

5 February 2009

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: February 5th, 2009

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc